Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2024 | Is there a role for combination therapy in CML?

Massimo Breccia • 4 Sep 2024
SOHO 2024
Chronic Myeloid Leukemia Leukemia Dasatinib Interferon Venetoclax

In this video, Massimo Breccia, MD, Sapienza University, Rome, Italy, briefly discusses the possibility of using combination therapies in the treatment of first-line chronic-phase chronic myeloid leukemia (CML), highlighting that combinations of agents that have previously been tested in trials have failed to demonstrate the desired efficacy. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Massimo Breccia

Mechanisms of resistance to TKIs in CML
1:35
Mechanisms of resistance to TKIs in CML
Massimo Breccia • 6 Dec 2025
ASC4OPT: asciminib in two dosing schedules in patients with CML resistant or intolerant to 2+ TKIs
1:06
ASC4OPT: asciminib in two dosing schedules in patients with CML resistant or intolerant to 2+ TKIs
Massimo Breccia • 6 Dec 2025
Mechanisms of resistance to the TKI asciminib in CML
1:16
Mechanisms of resistance to the TKI asciminib in CML
Massimo Breccia • 4 Sep 2024
Treatment-free remission after second-generation TKI treatment in CML
1:01
Treatment-free remission after second-generation TKI treatment in CML
Massimo Breccia • 4 Sep 2024

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals